Serious adverse events stratified by baseline diuretic use, pooled across the STEP-HFpEF and STEP-HFpEF-DM trials
| Adverse event, n (%) . | Diuretic group . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No diuretic . | Non-loop diuretic . | Loop diuretic < 40 mg/day . | Loop diuretic = 40 mg/day . | Loop diuretic > 40 mg/day . | ||||||
| Semaglutide n = 120 . | Placebo n = 100 . | Semaglutide n = 109 . | Placebo n = 114 . | Semaglutide n = 110 . | Placebo n = 109 . | Semaglutide n = 152 . | Placebo n = 157 . | Semaglutide n = 82 . | Placebo n = 92 . | |
| Serious adverse events | 13 (10.8) | 25 (25.0) | 16 (14.7) | 24 (21.1) | 11 (10.0) | 24 (22.0) | 25 (16.4) | 48 (30.6) | 25 (30.5) | 38 (41.3) |
| Serious adverse events leading to permanent treatment discontinuation | 1 (0.8) | 1 (1.0) | 3 (2.8) | 4 (3.5) | 0 (0.0) | 2 (1.8) | 3 (2.0) | 6 (3.8) | 5 (6.1) | 4 (4.3) |
| Cardiac serious adverse events | 2 (1.7) | 12 (12.0) | 5 (4.6) | 10 (8.8) | 5 (4.5) | 9 (8.3) | 8 (5.3) | 22 (14.0) | 6 (7.3) | 17 (18.5) |
| Gastrointestinal serious adverse events | 0 (0.0) | 1 (1.0) | 2 (1.8) | 2 (1.8) | 2 (1.8) | 1 (0.9) | 5 (3.3) | 5 (3.2) | 3 (3.7) | 3 (3.3) |
| COVID-19-related adverse events | 14 (11.7) | 15 (15.0) | 13 (11.9) | 12 (10.5) | 14 (12.7) | 14 (12.8) | 19 (12.5) | 22 (14.0) | 13 (15.9) | 17 (18.5) |
| Adverse event, n (%) . | Diuretic group . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No diuretic . | Non-loop diuretic . | Loop diuretic < 40 mg/day . | Loop diuretic = 40 mg/day . | Loop diuretic > 40 mg/day . | ||||||
| Semaglutide n = 120 . | Placebo n = 100 . | Semaglutide n = 109 . | Placebo n = 114 . | Semaglutide n = 110 . | Placebo n = 109 . | Semaglutide n = 152 . | Placebo n = 157 . | Semaglutide n = 82 . | Placebo n = 92 . | |
| Serious adverse events | 13 (10.8) | 25 (25.0) | 16 (14.7) | 24 (21.1) | 11 (10.0) | 24 (22.0) | 25 (16.4) | 48 (30.6) | 25 (30.5) | 38 (41.3) |
| Serious adverse events leading to permanent treatment discontinuation | 1 (0.8) | 1 (1.0) | 3 (2.8) | 4 (3.5) | 0 (0.0) | 2 (1.8) | 3 (2.0) | 6 (3.8) | 5 (6.1) | 4 (4.3) |
| Cardiac serious adverse events | 2 (1.7) | 12 (12.0) | 5 (4.6) | 10 (8.8) | 5 (4.5) | 9 (8.3) | 8 (5.3) | 22 (14.0) | 6 (7.3) | 17 (18.5) |
| Gastrointestinal serious adverse events | 0 (0.0) | 1 (1.0) | 2 (1.8) | 2 (1.8) | 2 (1.8) | 1 (0.9) | 5 (3.3) | 5 (3.2) | 3 (3.7) | 3 (3.3) |
| COVID-19-related adverse events | 14 (11.7) | 15 (15.0) | 13 (11.9) | 12 (10.5) | 14 (12.7) | 14 (12.8) | 19 (12.5) | 22 (14.0) | 13 (15.9) | 17 (18.5) |
Serious adverse events stratified by baseline diuretic use, pooled across the STEP-HFpEF and STEP-HFpEF-DM trials
| Adverse event, n (%) . | Diuretic group . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No diuretic . | Non-loop diuretic . | Loop diuretic < 40 mg/day . | Loop diuretic = 40 mg/day . | Loop diuretic > 40 mg/day . | ||||||
| Semaglutide n = 120 . | Placebo n = 100 . | Semaglutide n = 109 . | Placebo n = 114 . | Semaglutide n = 110 . | Placebo n = 109 . | Semaglutide n = 152 . | Placebo n = 157 . | Semaglutide n = 82 . | Placebo n = 92 . | |
| Serious adverse events | 13 (10.8) | 25 (25.0) | 16 (14.7) | 24 (21.1) | 11 (10.0) | 24 (22.0) | 25 (16.4) | 48 (30.6) | 25 (30.5) | 38 (41.3) |
| Serious adverse events leading to permanent treatment discontinuation | 1 (0.8) | 1 (1.0) | 3 (2.8) | 4 (3.5) | 0 (0.0) | 2 (1.8) | 3 (2.0) | 6 (3.8) | 5 (6.1) | 4 (4.3) |
| Cardiac serious adverse events | 2 (1.7) | 12 (12.0) | 5 (4.6) | 10 (8.8) | 5 (4.5) | 9 (8.3) | 8 (5.3) | 22 (14.0) | 6 (7.3) | 17 (18.5) |
| Gastrointestinal serious adverse events | 0 (0.0) | 1 (1.0) | 2 (1.8) | 2 (1.8) | 2 (1.8) | 1 (0.9) | 5 (3.3) | 5 (3.2) | 3 (3.7) | 3 (3.3) |
| COVID-19-related adverse events | 14 (11.7) | 15 (15.0) | 13 (11.9) | 12 (10.5) | 14 (12.7) | 14 (12.8) | 19 (12.5) | 22 (14.0) | 13 (15.9) | 17 (18.5) |
| Adverse event, n (%) . | Diuretic group . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| No diuretic . | Non-loop diuretic . | Loop diuretic < 40 mg/day . | Loop diuretic = 40 mg/day . | Loop diuretic > 40 mg/day . | ||||||
| Semaglutide n = 120 . | Placebo n = 100 . | Semaglutide n = 109 . | Placebo n = 114 . | Semaglutide n = 110 . | Placebo n = 109 . | Semaglutide n = 152 . | Placebo n = 157 . | Semaglutide n = 82 . | Placebo n = 92 . | |
| Serious adverse events | 13 (10.8) | 25 (25.0) | 16 (14.7) | 24 (21.1) | 11 (10.0) | 24 (22.0) | 25 (16.4) | 48 (30.6) | 25 (30.5) | 38 (41.3) |
| Serious adverse events leading to permanent treatment discontinuation | 1 (0.8) | 1 (1.0) | 3 (2.8) | 4 (3.5) | 0 (0.0) | 2 (1.8) | 3 (2.0) | 6 (3.8) | 5 (6.1) | 4 (4.3) |
| Cardiac serious adverse events | 2 (1.7) | 12 (12.0) | 5 (4.6) | 10 (8.8) | 5 (4.5) | 9 (8.3) | 8 (5.3) | 22 (14.0) | 6 (7.3) | 17 (18.5) |
| Gastrointestinal serious adverse events | 0 (0.0) | 1 (1.0) | 2 (1.8) | 2 (1.8) | 2 (1.8) | 1 (0.9) | 5 (3.3) | 5 (3.2) | 3 (3.7) | 3 (3.3) |
| COVID-19-related adverse events | 14 (11.7) | 15 (15.0) | 13 (11.9) | 12 (10.5) | 14 (12.7) | 14 (12.8) | 19 (12.5) | 22 (14.0) | 13 (15.9) | 17 (18.5) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
